The enol tautomer of indole-3-pyruvic acid as a biological switch in stress responses

Advances in Experimental Medicine and Biology

Volumn 527, Issue , 2003, Pages 601-608

  Bartolini, Barbara ^b   Corniello, Cristina ^b   Sella, Antonio ^b   Somma, Francesca ^b   Politi, Vincenzo ^a  

^a Polifarma Res Centre   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; ENZYME; EXCITATORY AMINO ACID; GLUCOCORTICOID; INDOLEPYRUVIC ACID; KYNURENIC ACID DERIVATIVE; OXYGEN RADICAL; TAUTOMERASE; UNCLASSIFIED DRUG;

BIOSYNTHESIS; CHEMICAL STRUCTURE; CONFERENCE PAPER; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STRESS; TRANSAMINATION;

MAMMALIA;

EID: 1042302725     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0135-0_69     Document Type: Conference Paper

References (22)

1. V. Politi, M.V. Lavaggi, G. Di Stazio, and A. Margonelli, Indole-3-pyruvic acid as a direct precursor of kynurenic acid. In: Kynurenine and Serotonin Pathways, Edited by R. Schwarcz, S.N. Young, R.R. Brown, (Plenum Press, New York, 1991), pp 515-518.
2. M.N. Perkins, T.W. Stone, An iontophoretic investigation of the actions of convulsants kynurenines and their interaction with the endogenous excitant quinolinic acid, Brain Res. 247, 184-187 (1982).
3. T.W. Stone, Kynurenines in the CNS: from endogenous obscurity to therapeutic importance, Progress in Neurobiology 64, 185-218 (2001).
4. P. Russi, V. Carlà and F. Moroni, Indolpyruvic acid administration increases the brain content of kynurenic acid. Is this a new avenue to modulate excitatory amino acid receptors in vivo?, Biochem. Pharmacol. 38, 2405-2409 (1989)
5. J.A. Bentley, K.R. Farrar, S. Housley, G.F. Smith and W.C. Taylor, Some chemical and physiological properties of 3-indolpyruvic acid, Biochem. J. 64, 44-49, (1956).
6. J.M. Kaper, O. Gebhard, C.J. Van Den Berg and H. Veldstra, Studies on indolepyruvic acid. I Synthesis and paperchromatography, Arch. Biochem. Biophys. 103, 469-474 (1963).
7. K. Schwarz and A.A. Bitancourt, Further evidence of tautomerism in chromatograms of indolyl-3-pyruvic acid, Biochem. J. 75, 182-187 (1960).
8. K. Schwarz, Separation of enol and keto tautomers of aromatic piruvic acids by paper chromatography, Arch. Biochem. Biophys. 92, 168-175 (1961).
9. E. Rosengren, P. Aman, S. Thelin, C. Hansson, S. Ahlfors, P. Bjork, L. Jacobsson and H. Rorsman, The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase, FEBS Lett. 417, 85-88 (1997).
10. A. Dios, R.A. Mitchell, B. Aljabari, J. Lubetsky, K.A. O'Connor, H. Liao, P.D. Senter, K.R. Manogue, E. Lolis, C. Metz, R. Bucala, D.J.E. Callaway and Y. Al-Abed, Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity, J. Med. Chem. 45, 2410-2416 (2002).
11. D.R. Ziegler and J.P. Herman, Local integration of glutamate signaling in the hypothalamic paraventricular region: regulation of glucocorticoid stress responses, Endocrinology 141, 4801-4804 (2000).
12. F. Squadrito, R. Sturniolo, G.R. Trimarchi, G.M. Campo, G. De Luca, A. Gorini, and A. Caputi, Antihypertensive activity of indolepyruvic acid: a keto analogue of tryptophan, J. Cardiovasc. Pharmacol. 15, 102-108 (1990).
13. I.P. Lapin and V. Politi, Anxiolytic effect of indole-3-pyruvic acid (IPA) in mice, Pharmacol. Res. 28, 129-134 (1993).
14. G. Biagini, E. Merlo Pich, C. Carani, P. Marrama, J-A. Gustafsson, K. Fuxe and L.F. Agnati, Indole-pyruvic acid, a tryptophan ketoanalogue, antagonizes the endocrine but not the behavioral effects of repeated stress in a model of depression, Biol. Psychiatry 33, 712-719 (1993).
15. Z. Shamsi, N. Stanley, J. Yoon and I. Hindmarch, Effects of three doses of 3-indole pyruvic acid on subjective and objective measures of sleep and early morning performance, Human Psychopharmacol. 11, 235-239 (1996).
16. V. Politi, G. De Luca, V. Gallai, Puca and M. Comin, Clinical experiences with the use of indole-3-pyruvic acid, In Tryptophan, Serotonin, and Melatonin: basic aspects and applications. Edited by G. Huether, W. Kochen, T.J. Simat, H. Steinhart, (Kluwer Academic/Plenum Publishers, New York, 1999), pp 227-232.
17. L. Bacciottini, D.E. Pellegrini-Giampietro, F. Bongianni, G. De Luca, M. Beni, V. Politi and F. Moroni, Biochemical and behavioural studies on indole-pyruvic acid: a keto-analogue of tryptophan, Pharmacol. Res. Commun. 19, 803-817 (1987).
18. C. Ferretti, M. Blengio, P. Ghi and E. Genazzani, Differential effects of indolepyruvic acid and 5-hydroxytryptophan on indole metabolism in the pineal gland of the rat during the light-dark cycle, Eur. J. Pharmacol. 187, 345-356 (1990).
19. J.P. Herman and W.E. Cullinan, Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis, Trends Neurosci. 20, 78-84 (1997).
20. R.M. Sapolsky: "Stress, the ageing brain, and the mechanism of neuron death". The MIT Press, Cambridge. Massachusetts, 1992
21. V. Politi, M. Materazzi, G. De Luca, G. Di Stazio, Indolepyruvic acid pharmacological and clinical profile, In Advances in Tryptophan Research 1992, edited by I. Ishiguro, R. Kido, T. Nagatsu, Y. Nagamura, Y. Ohta, (Fujita Health University Press, Toyoake, 1992), pp 293-296.
22. R. Silvestri, G. Mento, M. Raffaele, G. De Luca, G. Buttini, C. Casella, A. Tisano, P. De Domenico, A.E. Di Rosa and R. Di Perri, Indole-3-pyruvic acid as a possible hypnotic agent in insomniac subjects, J. In. Med. Res. 19, 403-409 (1991).